secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2026-02-13T23:59:59+00:00
Accession:  0001193805-26-000129
Event type: other_material
Sentiment:  positive
Materiality: 0.95
Item codes: 1.01, 3.02, 8.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Immunic announces up to $400M private placement and board changes to fund MS trials
--------------------------------------------------------------------------------

- Gross proceeds of up to $400M from private placement led by BVF Partners, with $200M from pre-funded warrants at $0.873 each.
- Proceeds to fund completion of Phase 3 ENSURE trials in relapsing MS and initiation of Phase 3 in primary progressive MS.
- Simona Skerjanec appointed interim chair; Thor Nagel joins board; Maria Törnsén resigns.
- Company entered into royalty purchase agreement with Series B warrant holders for 5% synthetic royalty on vidofludimus calcium sales.
- Company plans to search for new CEO with commercial experience; Dr. Vitt to transition to senior scientific role.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380526000129/0001193805-26-000129-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380526000129/e665154_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-26-000129

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer